

**From:** [REDACTED] (SANTE)  
**Sent:** 24 July 2017 16:12  
**To:** [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED] (SANTE)  
**Subject:** BTO 24/07/2017 – Meeting between SANTE E4 and [REDACTED], from BEUC on the scientific criteria to identify endocrine disruptors (ED)

**BTO 24/07/2017 – Meeting between SANTE E4 and [REDACTED], from BEUC on the scientific criteria to identify endocrine disruptors (ED)**

Participants:

- SANTE E4: [REDACTED]
- BEUC [REDACTED] Project Officer on Chemicals and International Trade Agreements

The meeting took place on request of BEUC. The representative of BEUC started by recognising that the Commission had been extremely transparent on this file, publishing all the different versions of the drafts and the minutes of the meetings. This was very much appreciated. The representative of BEUC also expressed its satisfaction with the fact that the criteria did not include potency. He also recognised that there had been some improvements of the texts since their publication and that the interim criteria are not fit for purpose and should be changed as soon as possible.

BEUC then asked the following questions:

- what are the different timelines for the RPS measure and the delegated act
- why "known and presumed" is only mentioned in the recitals and not in the annex
- why "plausibility" is not mentioned in the three commandments
- what kind of data will companies need to produce to adjust to the criteria
- will new test guidelines be available soon
- will the GD on the implementation of the criteria be available for public consultation and when
- why are growth regulators exempted from the ED criteria when they are designed to have an ED mode of action
- how many substances would fall within the growth regulators provisions
- is there a system in place in the PPP regulation for flagging CMR cat 2
- will other sectors, and in particular cosmetics, take over the criteria without change or can they modify the criteria and introduce categories for instance
- when will the amendment to the derogation (negligible exposure to negligible risk from exposure) be discussed again
- what does the review clause mean in practice

SANTE answered according to the agreed LTT on ED.